Payment overview · 2025
General Payments
$2,141.62
118 reported records · 20 companies
Healthcare provider profile · identity verified
John Michael Bonham, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · ENGLEWOOD, TN · NPI 1811462906
Verified facts
What the public records show
CMS Open Payments records show John Michael Bonham, PA-C received $2,141.62 in general payments during 2025 across 118 reported records.
ABBVIE INC. accounted for 13.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Qulipta, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Qulipta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $294.07 | 13.7% | 32 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $279.47 | 13.1% | 13 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $211.61 | 9.9% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $198.69 | 9.3% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $167.85 | 7.8% | 10 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $152.91 | 7.1% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $137.70 | 6.4% | 6 | 2025 |
| Surgenex LLC | Unresolved — no canonical attribution shown | $125.24 | 5.8% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $85.15 | 4.0% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $61.29 | 2.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $60.03 | 2.8% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $58.82 | 2.8% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $57.07 | 2.7% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $56.20 | 2.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $55.75 | 2.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.13 | 2.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.42 | 1.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.07 | 1.1% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.78 | 1.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.37 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,141.62 | 118 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $315.01 | 16 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $211.61 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $204.04 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $190.14 | 24 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $167.30 | 22 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $152.91 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $131.76 | 8 | 2025 |
Source payment records
|
|||||
| ArdeoGraft Normalized: ardeograft |
Biological | Surgenex LLC | $125.24 | 3 | 2025 |
Source payment records
|
|||||
| PelloGraft Normalized: pellograft |
Biological | Surgenex LLC | $125.24 | 3 | 2025 |
Source payment records
|
|||||
| RenoGraft Normalized: renograft |
Biological | Surgenex LLC | $125.24 | 3 | 2025 |
Source payment records
|
|||||
| SurGraft Normalized: surgraft |
Biological | Surgenex LLC | $125.24 | 3 | 2025 |
Source payment records
|
|||||
| SurMatrix Normalized: surmatrix |
Biological | Surgenex LLC | $125.24 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $103.93 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $94.20 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $85.15 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $60.76 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $58.82 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $57.07 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.23 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $56.20 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.13 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $49.13 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $40.20 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.42 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| ALVESCO Normalized: alvesco |
Drug | Azurity Pharmaceuticals, Inc. | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $7.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 15 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 33 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | 14 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 150 | 68 |
| Lisinopril | Lisinopril | 115 | 49 |
| Omeprazole | Omeprazole | 111 | 48 |
| Meloxicam | Meloxicam | 83 | 32 |
| Trazodone Hcl | Trazodone Hcl | 80 | 34 |
| Prednisone | Prednisone | 76 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 75 | 35 |
| Losartan Potassium | Losartan Potassium | 73 | 29 |
| Gabapentin | Gabapentin | 69 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 30 |
| Amlodipine Besylate | Amlodipine Besylate | 61 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 51 |
| Furosemide | Furosemide | 53 | 23 |
| Metformin Hcl | Metformin Hcl | 51 | 23 |
| Azithromycin | Azithromycin | 50 | 43 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 26 |
| Famotidine | Famotidine | 45 | 19 |
| Montelukast Sodium | Montelukast Sodium | 44 | 19 |
| Sertraline Hcl | Sertraline Hcl | 44 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 18 |
| Alprazolam | Alprazolam | 42 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 11 |
| Baclofen | Baclofen | 40 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 31 |
| Fluconazole | Fluconazole | 37 | 18 |
| Potassium Chloride | Potassium Chloride | 37 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 36 | 17 |
| Tramadol Hcl | Tramadol Hcl | 36 | 14 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 33 | 12 |
| Ozempic | Semaglutide | 33 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 31 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 13 |
| Buspirone Hcl | Buspirone Hcl | 29 | 12 |
| Doxepin Hcl | Doxepin Hcl | 29 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 26 |
| Lorazepam | Lorazepam | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 26 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 26 | 14 |
| Carvedilol | Carvedilol | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | 11 |
| Sucralfate | Sucralfate | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Simvastatin | Simvastatin | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | 12 |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Ofloxacin | Ofloxacin | 16 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | 11 |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Qulipta | Atogepant | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Eliquis | Apixaban | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,141.62 · 118 records | ABBVIE INC. | AFREZZA, AIRSUPRA, ALVESCO, ArdeoGraft, Auvelity, BREZTRI, CAPLYTA, EVENITY, FARXIGA, JARDIANCE, KRYSTEXXA, Korlym, MOUNJARO, OTEZLA, Ohtuvayre, Ozempic, PelloGraft, QULIPTA, REPATHA, REXULTI, RenoGraft, Rybelsus, SHINGRIX, SurGraft, SurMatrix, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VRAYLAR, VYEPTI, VYNDAMAX, Veozah, Wegovy, XIFAXAN, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error